Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib by Alexander P. Bye, Amanda J. Unsworth,

Slides:



Advertisements
Similar presentations
Acalabrutinib and ibrutinib therapy cause dysfunctional GPVI-mediated platelet aggregation. Acalabrutinib and ibrutinib therapy cause dysfunctional GPVI-mediated.
Advertisements

Human platelets produced in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice upon transplantation of human cord blood CD34+ cells are.
by Wei Zhang, and Robert W. Colman
Reduced thrombus stability in mice lacking the α2A-adrenergic receptor
Activation of αIIbβ3 is a sufficient but also an imperative prerequisite for activation of α2β1 on platelets by Gerlinde R. Van de Walle, Anne Schoolmeester,
Protein kinase B (PKB/c-akt) regulates homing of hematopoietic progenitors through modulation of their adhesive and migratory properties by Miranda Buitenhuis,
by Matt W. Goschnick, Lai-Man Lau, Janet L. Wee, Yong S. Liu, P
Occlusive thrombi arise in mammals but not birds in response to arterial injury: evolutionary insight into human cardiovascular disease by Alec A. Schmaier,
by Kathryn Lagrue, Alex Carisey, David J
Highly electronegative LDL from patients with ST-elevation myocardial infarction triggers platelet activation and aggregation by Hua-Chen Chan, Liang-Yin.
PRT , a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model by Michael P. Reilly, Uma Sinha,
Vessel wall BAMBI contributes to hemostasis and thrombus stability
by Kesheng Dai, Richard Bodnar, Michael C. Berndt, and Xiaoping Du
by Hong Yin, Aleksandra Stojanovic, Nissim Hay, and Xiaoping Du
Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin αIIbβ3 by Cindy L. Yap, Karen.
Recombinant factor VIIa restores aggregation of αIIbβ3-deficient platelets via tissue factor–independent fibrin generation by Ton Lisman, Jelle Adelmeijer,
Effects of inflammatory cytokines on the release and cleavage of the endothelial cell–derived ultralarge von Willebrand factor multimers under flow by.
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas by Pankaj Gupta,
Agonist-induced aggregation of Chinese hamster ovary cells coexpressing the human receptors for fibrinogen (integrin αIIbβ3) and the platelet-activating.
by Zhengyan Wang, Tina M. Leisner, and Leslie V. Parise
by Jun Chung, Xue-Qing Wang, Frederik P. Lindberg, and William A
Inhibition of collagen-induced platelet aggregation by anopheline antiplatelet protein, a saliva protein from a malaria vector mosquito by Shigeto Yoshida,
Alterations in platelet secretion differentially affect thrombosis and hemostasis by Smita Joshi, Meenakshi Banerjee, Jinchao Zhang, Akhil Kesaraju, Irina.
Identification of FcγRIIa as the ITAM-bearing receptor mediating αIIbβ3 outside-in integrin signaling in human platelets by Brian Boylan, Cunji Gao, Vipul.
BCL2/BCL-XL inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation by Meike Vogler, Hassan A. Hamali, Xiao-Ming.
A role for the thiol isomerase protein ERP5 in platelet function
by Bruno Bernardi, Gianni F. Guidetti, Francesca Campus, Jill R
Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy by Mark P. Chao, Chad Tang, Russell K. Pachynski,
Impaired activation of platelets lacking protein kinase C-θ isoform
Oxidized low-density lipoproteins induce rapid platelet activation and shape change through tyrosine kinase and Rho kinase–signaling pathways by Katie.
C1qTNF–related protein-1 (CTRP-1): a vascular wall protein that inhibits collagen-induced platelet aggregation by blocking VWF binding to collagen by Gerald.
Phosphorylation of CLEC-2 is dependent on lipid rafts, actin polymerization, secondary mediators, and Rac by Alice Y. Pollitt, Beata Grygielska, Bertrand.
Vascular endothelial growth factor stimulates protein kinase CβII expression in chronic lymphocytic leukemia cells by Simon T. Abrams, Benjamin R. B. Brown,
Volume 16, Issue 12, Pages (December 2008)
IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation and thrombus formation by Melanie Antl, Marie-Luise von Brühl, Christina Eiglsperger,
Rapid ubiquitination of Syk following GPVI activation in platelets
Diverging signaling events control the pathway of GPVI down-regulation in vivo by Tamer Rabie, David Varga-Szabo, Markus Bender, Rastislav Pozgaj, Francois.
RGS10 shapes the hemostatic response to injury through its differential effects on intracellular signaling by platelet agonists by Peisong Ma, Shuchi Gupta,
Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells by Uri Rozovski, Ji Yuan Wu, David.
Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation by Alexandra Mazharian, Cedric Ghevaert, Lin Zhang, Steffen Massberg,
In-depth PtdIns(3,4,5)P3 signalosome analysis identifies DAPP1 as a negative regulator of GPVI-driven platelet function by Tom N. Durrant, James L. Hutchinson,
Dichloroacetate, an inhibitor of pyruvate dehydrogenase kinases, inhibits platelet aggregation and arterial thrombosis by Manasa K. Nayak, Nirav Dhanesha,
Protein kinase C signaling dysfunction in von Willebrand disease (p
Inter-α inhibitor proteins maintain neutrophils in a resting state by regulating shape and reducing ROS production by Soe Soe Htwe, Hidenori Wake, Keyue.
Platelet-specific deletion of SNAP23 ablates granule secretion, substantially inhibiting arterial and venous thrombosis in mice by Christopher M. Williams,
A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant by Shauna L. French, Claudia Thalmann, Paul F.
by Silvia Mele, Stephen Devereux, Andrea G
Rap1 binding to the talin 1 F0 domain makes a minimal contribution to murine platelet GPIIb-IIIa activation by Frederic Lagarrigue, Alexandre R. Gingras,
Specific Synergy of Multiple Substrate–Receptor Interactions in Platelet Thrombus Formation under Flow  Brian Savage, Fanny Almus-Jacobs, Zaverio M Ruggeri 
Platelet heterogeneity in activation-induced glycoprotein shedding: functional effects by Constance C. F. M. J. Baaten, Frauke Swieringa, Tomasz Misztal,
Janina Jamasbi et al. BTS 2016;1:
Janina Jamasbi et al. BTS 2016;1:
The endogenous antimicrobial cathelicidin LL37 induces platelet activation and augments thrombus formation by Maryam F. Salamah, Divyashree Ravishankar,
ELMO1 deficiency enhances platelet function
Soluble GPVI is elevated in injured patients: shedding is mediated by fibrin activation of GPVI by Samantha J. Montague, Céline Delierneux, Christelle.
Characterization of the activity of RBCs bound by hTM-scFv fusions and their therapeutic efficacy in a microfluidic model of inflammatory thrombosis. Characterization.
L.S. Quek, J. Bolen, S.P. Watson  Current Biology 
Protein Kinase D Inhibitors Uncouple Phosphorylation from Activity by Promoting Agonist-Dependent Activation Loop Phosphorylation  Maya T. Kunkel, Alexandra C.
Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL by Kallesh D. Jayappa, Craig A.
The platelet NLRP3 inflammasome is upregulated in sickle cell disease via HMGB1/TLR4 and Bruton tyrosine kinase by Sebastian Vogel, Taruna Arora, Xunde.
by Caroline Kardeby, Knut Fälker, Elizabeth J
Interleukin-2–inducible T-cell kinase inhibitors modify functional polarization of human peripheral T-cell lymphoma cells by Sami Mamand, Matthew Carr,
Calpain cleaves phospholipid flippase ATP8A1 during apoptosis in platelets by Weidong Jing, Mehmet Yabas, Angelika Bröer, Lucy Coupland, Elizabeth E. Gardiner,
TREM-like transcript 1: a more sensitive marker of platelet activation than P-selectin in humans and mice by Christopher W. Smith, Zaher Raslan, Lola Parfitt,
Secretion is ablated in the absence of SNAP23.
by Kelly E. Johnson, Julia R. Ceglowski, Harvey G. Roweth, Jodi A
Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies by Nadine Müller-Calleja, Svenja.
Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura by Liang Zheng, Yingying.
by Alyssa J. Moroi, Nicole M. Zwifelhofer, Matthew J. Riese, Debra K
Src kinases mediate TSP-1 inhibition of AC and PKA activity.
Presentation transcript:

Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib by Alexander P. Bye, Amanda J. Unsworth, Michael J. Desborough, Catherine A. T. Hildyard, Niamh Appleby, David Bruce, Neline Kriek, Sophie H. Nock, Tanya Sage, Craig E. Hughes, and Jonathan M. Gibbins BloodAdv Volume 1(26):2610-2623 December 12, 2017 © 2017 by The American Society of Hematology

Alexander P. Bye et al. Blood Adv 2017;1:2610-2623 © 2017 by The American Society of Hematology

Acalabrutinib and ibrutinib therapy cause dysfunctional GPVI-mediated platelet aggregation. Acalabrutinib and ibrutinib therapy cause dysfunctional GPVI-mediated platelet aggregation. PRP from patients receiving ibrutinib (Ibr; n = 6), acalabrutinib (Acal; n = 7), healthy donors (n = 9), or Btk inhibitor naïve CLL patients (n = 5) was loaded into 96-well microtiter plates containing lyophilized platelet agonists. Plates were shaken for 5 minutes at 37°C and aggregation was measure by light transmission to give an end point measurement. (A) Scatter plot of EC50 values calculated from concentration response curves for ADP, U46619, epinephrine, TRAP-6, CRP-XL, and collagen. Each point represents the response of a patient receiving acalabrutinib (red triangle) or ibrutinib (green square); healthy donor (gray circle) or Btk inhibitor naïve CLL patient (white diamond). NR, patients that did not respond to an agonist at the highest concentration tested. Concentration response curves for GPVI agonists (B) CRP-XL and (C) collagen; each point represents the mean % aggregation values ± standard error of the mean (SEM). Significant differences relative to healthy donors were tested by 2-way ANOVA with the Turkey multiple comparisons test. Aggregation of washed platelets from healthy donors pre-treated with a range of (D) acalabrutinib or (E) ibrutinib concentrations and then stimulated with 3 to 0.01 µg/mL CRP-XL. Alexander P. Bye et al. Blood Adv 2017;1:2610-2623 © 2017 by The American Society of Hematology

SFK activation and adhesion to collagen is spared by acalabrutinib but not ibrutinib. SFK activation and adhesion to collagen is spared by acalabrutinib but not ibrutinib. Washed human platelets from healthy donors were preincubated with a range of (A) acalabrutinib or (B) ibrutinib and then stimulated with 1 µg/mL CRP-XL for 3 minutes at 37°C; tyrosine phosphorylation of Src (Y418) and Btk (Y223) were measured by western blot using site-specific antibodies and total levels of Tec tyrosine phosphorylation were measure by ELISA. Points represent mean levels of tyrosine phosphorylation relative to vehicle-treated controls ± SEM. (C) Representative images of phosphoblots. Washed platelets treated with a range of acalabrutinib, ibrutinib, or dasatinib concentrations and stimulated as previously and blotted for (D) tyrosine phosphorylation of Lyn (Y396) or (E) total phosphotyrosine using a site-specific antibody or 4G10, respectively. Points represent mean levels of tyrosine phosphorylation relative to vehicle-treated controls ± SEM. (F) Aggregation 1 µg/ml CRP-XL stimulated of washed platelets was performed in 96-well plates after treatment with a range of concentrations of acalabrutinib, ibrutinib, or dasatinib concentration response curves are mean platelet aggregation ± SEM relative to vehicle-treated control. (G) Acalabrutinib, ibrutinib, or dasatinib-treated washed platelets from healthy donors were allowed adhere to collagen-coated wells of a 96-well plate after 45 minutes at 37°C; graphs plot concentration response curves to mean numbers of adhered platelets ± SEM relative to vehicle treatment. (H) Representative images of phosphoblots for platelets treated with tyrosine kinase inhibitors. Alexander P. Bye et al. Blood Adv 2017;1:2610-2623 © 2017 by The American Society of Hematology

Acalabrutinib inhibits signal transduction downstream of GPVI with lower potency than ibrutinib. Acalabrutinib inhibits signal transduction downstream of GPVI with lower potency than ibrutinib. Washed human platelets from healthy donors were preincubated with a range of acalabrutinib or ibrutinib concentrations and then stimulated with 1 µg/mL CRP-XL for 3 minutes at 37°C and phosphorylation of (A) PLCγ2 (Y759) and (B) PKC substrates (S/T) was measured by western blotting. (C) Representative western blot images for PLCγ2 (Y759) and S/T phosphorylated PKC substrates. (D) Cytosolic Ca2+ following stimulation with 1 µg/mL CRP-XL was measured in fura-2 loaded platelets in real time for 5 minutes. Points represent the mean response relative to vehicle ± SEM. Representative [Ca2+]i traces following incubation with (E) acalabrutinib or (F) ibrutinib. Alexander P. Bye et al. Blood Adv 2017;1:2610-2623 © 2017 by The American Society of Hematology

Acalabrutinib is a less potent inhibitor of integrin αIIb β3 activation and granule secretion than ibrutinib. Acalabrutinib is a less potent inhibitor of integrin αIIbβ3activation and granule secretion than ibrutinib. Washed human platelets from healthy donors were preincubated with a range of acalabrutinib or ibrutinib concentrations and then stimulated with 1 µg/mL CRP-XL for 20 minutes. (A) P-selectin and (B) fibrinogen binding was measured by fluorescence-activated cell sorting. (C) Platelets were stimulated with 1 µg/mL CRP-XL for 3 minutes at 37°C. Phosphorylation of β3 (Y773) was measured by western blotting. Points represent mean responses relative to vehicle ± SEM. (D) Representative β3 (Y773) blots. Alexander P. Bye et al. Blood Adv 2017;1:2610-2623 © 2017 by The American Society of Hematology

Ibrutinib, but not acalabrutinib, causes thrombus instability. Ibrutinib, but not acalabrutinib, causes thrombus instability. Whole blood from healthy donors was incubated with vehicle, 1 µM ibrutinib, and 1 µM acalabrutinib for 20 minutes and flowed through collagen-coated microfluidic flow chambers at a shear rate of 1000 s−1 for 6 minutes. (A) Representative images of thrombi formed under each of the conditions tested at 2-minute intervals. (B) A summary of effects of 1 µM ibrutinib and 1 µM acalabrutinib on thrombus formation on collagen and other platelet signaling and functional measurements relative to vehicle-treated control. Bars represent the mean ± SD; P values were calculated using multiple tests with Holm-Sidak correction for multiple comparisons. Alexander P. Bye et al. Blood Adv 2017;1:2610-2623 © 2017 by The American Society of Hematology

Thrombus formation on collagen correlates with platelet count during treatment with acalabrutinib but not with ibrutinib. Thrombus formation on collagen correlates with platelet count during treatment with acalabrutinib but not with ibrutinib. (A) Blood from healthy donors (n = 6), Btk-inhibitor naïve CLL patients (n = 5), patients receiving ibrutinib (n = 6) or acalabrutinib (n = 8) was perfused through collagen-coated microfluidic flow chambers at room temperature at a shear rate of 1000 s−1 before being fixed with 10% formyl saline. Fixed samples were stained with DioC6 and z-stack images acquired to enable estimation of thrombus volume. (A) Representative images of thrombi in blood from a healthy donor and patients in the presence or absence of Haemate P (intermediate factor VIII) added ex vivo. Thrombus volume plotted against platelet count for (B) Btk inhibitor naïve CLL patients; patients treated with (C) acalabrutinib or (D) ibrutinib with or without added Haemate P. Correlation between platelet count and thrombus volume is significant in the presence or absence of Haemate P for acalabrutinib patients (significantly nonzero, P ≤ .05) but nonsignificant for ibrutinib patients (P > .05). Alexander P. Bye et al. Blood Adv 2017;1:2610-2623 © 2017 by The American Society of Hematology

Platelet function is improved by ex vivo addition of Haemate P Platelet function is improved by ex vivo addition of Haemate P. Comparison of the volume of thrombi formed in the presence or absence of Haemate P added ex vivo to blood from healthy donors (n = 6), Btk inhibitor naïve CLL patients (n = 5), or patients receiving ibrutinib (n = 6) or acalabrutinib (n = 8, as described in Figure 7). Platelet function is improved by ex vivo addition of Haemate P. Comparison of the volume of thrombi formed in the presence or absence of Haemate P added ex vivo to blood from healthy donors (n = 6), Btk inhibitor naïve CLL patients (n = 5), or patients receiving ibrutinib (n = 6) or acalabrutinib (n = 8, as described in Figure 7). Two-way ANOVA with repeated measures and Sidak multiple comparisons test. Alexander P. Bye et al. Blood Adv 2017;1:2610-2623 © 2017 by The American Society of Hematology